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Background: Individuals may still develop gastric cancer (GC) even after H. pylori 1 
(HP) eradication. We aimed to investigate statin effect on GC development in HP-2 
eradicated subjects. 3 
Methods: All adult subjects who were prescribed clarithromycin-based triple therapy 4 
between 2003 and 2012 were identified in this retrospective cohort study utilizing a 5 
territory-wide electronic healthcare database. Patients were observed from index date 6 
of HP therapy, and censored at GC diagnosis, death or December 2015 (study end 7 
date). Statin use was defined as ≥ 180-day use after index date. Exclusion criteria 8 
included GC diagnosed within the first year after index date, previous GC or 9 
gastrectomy, and HP treatment failure. Subdistribution hazard ratio (SHR) of GC with 10 
statins was calculated by competing risk regression with propensity score (PS) 11 
analysis matching 19 variables (age, sex, comorbidities and other drug usage 12 
including proton pump inhibitors, non-steroidal anti-inflammatory drugs, aspirin, 13 
cyclooxygenase-2 inhibitors, and metformin).  14 
Results: During a median follow-up of 7.6 years (IQR: 5.1–10.3), 169 (0.27%) of 15 
63,605 patients developed GC at an incidence rate of 3.5 per 10,000 person-years. 16 
Among 22,870 PS-matched subjects, statins were associated with a lower GC risk 17 
(SHR 0.34; 95% CI:0.19-0.61), in a duration- and dose-response manner (p-18 
trend<0.05).  19 
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Conclusion: Statins associated a lower GC risk in a duration- and dose-response 1 
manner among HP-eradicated patients. 2 
Impact: This study provides evidence on the additional benefits of statins as 3 
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Globally, gastric cancer is the fifth most common cancer and third leading cause of 1 
cancer-related death.1 Helicobacter pylori (H. pylori) is the most important etiological 2 
agent of gastric cancer (more than 3-fold increase in risk).2,3 As eradication of H. 3 
pylori only reduces gastric cancer risk by 47%,4, 5 there is still an unmet need to 4 
identify chemopreventive agents against gastric cancer. 5 
 6 
Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (an 7 
enzyme involved in cholesterol synthesis), and are used for primary and secondary 8 
prevention of cardiovascular diseases.6 In addition to their lipid lowering effect, 9 
statins have potential chemopreventive effects on various solid organ tumours, which 10 
are believed to be mediated via arresting cell-cycle progression, inducing apoptosis, 11 
inhibiting angiogenesis, and immunomodulation.7 Lovastatin has been shown to 12 
suppress genes involved in cell division, upregulate cell cycle inhibitors and suppress 13 
anti-apoptotic proteins in human gastric cancer-derived cell lines.8 In addition, statins 14 
inhibit gastric cancer cell growth in mice models.9 15 
 16 
As yet, there is no randomized clinical trial (RCT) dedicated to investigate the effect 17 
of statins on gastric cancer as the primary outcome. Observational studies, on the 18 
other hand, yield conflicting results with some studies showing a lower gastric cancer 19 
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risk by statins,10-13 while others failed to show such a benefit.14-20 Although a recent 1 
meta-analysis conclude that statins were associated with lower gastric cancer risk,21 2 
all included studies enrolled both H. pylori-infected and H. pylori-negative subjects. 3 
In addition, few studies stratified the cancer risk according to cancer location of non-4 
cardia and cardia, as etiological factors are different for these two cancer subtypes, 5 
with H. pylori infection and gastroesophageal reflux disease being the major risk 6 
factors for non-cardia and cardia cancer, respectively.2, 22 However, in areas where H. 7 
pylori are prevalent, both non-cardia and cardia gastric cancer could be associated 8 
with H. pylori infection.2 To date, there are no studies that specifically investigate the 9 
potential chemopreventive role of statins in gastric cancer prevention after H. pylori 10 
eradication. Therefore, we conducted this territory-wide study to determine the 11 
potential effect of statins on gastric cancer risk with stratification to cancer subsites 12 
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Study design and data source  1 
This was a retrospective cohort study based on data retrieved from the territory-wide 2 
electronic healthcare database, Clinical Data Analysis and Reporting System 3 
(CDARS), of the Hong Kong Hospital Authority. The Hospital Authority is the only 4 
public-funded healthcare provider in Hong Kong with a population of around 7.3 5 
million, covering 87-94% of all secondary and tertiary care in the territory during the 6 
study period.23 Essential clinical information such as patient’s demographics, death, 7 
diagnoses, drug dispensing records, procedures and laboratory results, hospitalization 8 
records, attendance of outpatient clinics and emergency departments are all recorded 9 
in CDARS. Prescription and dispensing are performed at the same time, and 10 
prescription record generally matches the dispensing record. Various studies utilizing  11 
CDARS were undertaken,24-27 demonstrating a high diagnostic coding accuracy 12 
(International Classification of Diseases, Ninth Revision [ICD-9]) with positive and 13 
negative predictive values of more than 85–90%.  14 
 15 
This study was conducted in accordance with Declaration of Helsinki. Each patient 16 
was assigned an anonymous identifier (reference key) in CDARS to protect 17 
confidentiality. Therefore, written informed consent was not required with ethics 18 
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approval obtained from the Institutional Review Board of the University of Hong 1 
Kong and the Hong Kong West Cluster of the Hospital Authority.  2 
 3 
Study Subjects  4 
All H. pylori-infected adults aged ≥18 years who had received a course of 5 
clarithromycin-based triple therapy for H. pylori between 1 January 2003 and 31 6 
December 2012 (i.e. index date) were identified from CDARS. The use of triple 7 
therapy was identified by co-prescription of one of the proton pump inhibitors (PPIs) 8 
with clarithromycin and either amoxicillin or metronidazole with the correct doses, 9 
same prescription start date and a treatment duration of 7-14 days as previously 10 
described.25, 26 Clarithromycin-based triple therapy was the first-line treatment for H. 11 
pylori due to the low clarithromycin resistance rate (8%)28 and high eradication rate 12 
(> 90%) in Hong Kong during the study period.29 Endoscopy-based tests (including 13 
histology and rapid urease test) as well as urea breath test are the only diagnostic tests 14 
for H. pylori infection available in local public hospitals.  15 
 16 
Exclusion criteria were: (1) gastric cancer development within the first year of index 17 
date (to exclude prevalent cases due to possibly missed/delayed diagnosis); (2) history 18 
of gastric cancer or gastrectomy before index date; (3) triple therapy failure. Due to 19 
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unavailability of  direct ICD-9 code, triple therapy failure was inferred by repeated 1 
clarithromycin-based triple therapy, or requirement of a second-line therapy (either 2 
PPI-levofloxacin-amoxycillin or bismuth-based quadruple therapy), or a third-line 3 
therapy (rifabutin-based therapy). Subject recruitment process is depicted in Figure 1.  4 
 5 
Study Outcome and data validation 6 
The outcome of interest was gastric adenocarcinoma. We observed the patients from 7 
index date, and they were censored at cancer diagnosis, death or study end date (31 8 
December 2015). Supplementary Table 1 shows the ICD-9 codes for gastric 9 
adenocarcinoma. The date of cancer diagnosis was the earliest date of hospitalization 10 
for treatment and/or workup.  11 
 12 
As individuals are anonymized in CDARS, we could only validate the outcome of 13 
subjects in our institution (Queen Mary Hospital) which is an acute hospital and a 14 
tertiary referral center. The clinical details of 14 (8.3%) patients with gastric cancer 15 
were reviewed, with all fulfilling the selection criteria. Histology reports revealed all 16 
cases being adenocarcinoma without H. pylori infection.    17 
 18 
Exposure of interest and covariates 19 
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The exposure of interest was statin usage after index date. Simvastatin, atorvastatin 1 
and rosuvastatin were the only statins available in the public hospitals. Covariates 2 
used for propensity score (PS) matching (described in details in later section) included 3 
the age of receiving triple therapy, sex, alcohol use, smoking, prior peptic ulcer 4 
disease, diabetes mellitus,30 and other comorbidities (hypertension, dyslipidemia, 5 
ischemic heart disease, atrial fibrillation, congestive heart failure, stroke, cirrhosis, 6 
and chronic renal failure) as well as usage of other drugs (non-steroidal anti-7 
inflammatory drugs [NSAIDs], aspirin,25 cyclooxygenase-2 [COX-2] inhibitors, 8 
metformin26 and PPIs31) (Table 1). As the true prevalence of smoking and alcoholism 9 
may be underestimated by diagnosis coding only, a large set of comorbidities were 10 
included to serve as surrogate markers of these two imperfectly measured 11 
confounders. The diagnosis codes of these variables are shown in Supplementary 12 
Table 1.  13 
 14 
We defined statin exposure (as well as other medications) as ≥180-day use after index 15 
date during the observation period according to Lee et al11. The date of prescription, 16 
daily dose, and duration of each prescription were collected. To investigate dose-17 
response relationship, we quantified statin use based on the defined daily doses 18 
(DDDs) to unify the dose for different statins (one DDD is equivalent to simvastatin 19 
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30mg, atrovastatin 20mg and rosuvastatin 10mg).32 With this approach, the cDDD 1 
would take both the potency and quantity of statins into consideration, which is a 2 
common proxy for both duration and dose effect of different statins. Cumulative DDD 3 
(cDDD) was then derived by summing the DDDs of any statins during observation 4 
period. To investigate the duration-response relationship, statin use was categorized 5 
into three groups: (i) non-statin use, (ii) < 5 years, and (iii) ≥ 5 years.  6 
 7 
Statistical analyses  8 
We used R version 3.2.3 (R Foundation for Statistical Computing) statistical software 9 
to perform the statistical analyses. We expressed continuous variables as median and 10 
interquartile range (IQR). PS analysis was used to control for confounding due to 11 
unbalance in treatment allocation. PS was derived by multivariable logistic regression 12 
taking various covariates (age, sex, comorbidities and concurrent medications) into 13 
consideration. As such, any difference in cancer risk would be theoretically ascribed 14 
to statin effect solely. Furthermore, we excluded individuals in the extreme ends of PS  15 
distribution to reduce the effect of unmeasured confounding.33 Twenty categories of 16 
5% each for the PS distribution were created, followed by trimming of the first and 17 
20th PS categories (i.e. PS trimming).  18 
 19 
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We used PS matching as the primary analysis to calculate gastric cancer risk with 1 
statin usage with reference to non-statin usage. Statin users were matched to non-2 
statin users in a 1:1 ratio with replacement using a greedy distance-based matching 3 
algorithm with the logit of the PS within 0.1 standard deviation. Due to the strict 4 
matching criteria, the final patient number was 11,678 and 11,192 in statin and non-5 
statin groups. The balance of covariates between the two groups was assessed by 6 
absolute standardized difference (ASD), which was derived from the absolute 7 
difference in means or proportions divided by the pooled standard deviation. An ASD 8 
of < 0.20 indicates good balance for a particular covariate. Imbalance covariates with 9 
ASD > 0.20 after matching were adjusted for in the competing regression risk 10 
model.34 11 
 12 
Competing risk regression model was used to estimate the subdistribution hazard ratio 13 
(SHR),35 as death was a competing risk for gastric cancer with statin users having 14 
higher cardiovascular risk (Table 1) and thus mortality. Stratified analysis was 15 
performed according to the location of gastric cancer (cardia and non-cardia regions), 16 
as the underlying carcinogenic mechanisms differ.22 The PS adjusted absolute 17 
difference in cancer risk between the two groups was derived by (adjusted HR – 1) x  18 
(crude incidence rate of gastric cancer in non-statin users). The duration- and dose-19 
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response relationship between statins and gastric cancer was derived by the competing 1 
risk regression model using PS adjustment after trimming. The trend for duration-2 
response of statins was assessed by Cochran-Armitage test. The survival difference 3 
between the statin and non-statin users was illustrated in terms of Kaplan-Meier curve 4 
and log-rank p-value.  5 
 6 
Sensitivity analyses were conducted by (1) changing the days of exposure to define 7 
statin use (≥ 30 and ≥ 90 days), (2) not including other comorbidities except for peptic 8 
ulcer disease and diabetes mellitus, (3) PS regression adjustment with trimming (with 9 
all covariates included into the competing risk regression model), (4) multivariable 10 
analysis as well as (5) Cox proportional hazards model (effect estimate expressed as 11 
adjusted HR). ‘Complementary log-log’-scaled Kaplan-Meier plot and schoenfeld 12 
residuals for statin use (p-value > 0.05) confirmed non-violation of the Cox 13 
proportional-hazard assumption. Prior statin users (defined as individuals with any 14 
statin prescription within two years before the index date) were excluded in further 15 
sensitivity analysis. 16 
 17 
To address potential immortal time bias that may spuriously augment the beneficial 18 
effect of a drug,36 further sensitivity analysis was performed by treating all 19 
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medications including statins as time-varying covariates in the multivariable Cox 1 
model,37 in which the observation period was disintegrated into yearly intervals and 2 
medication usage was defined as ≥90-day use in each interval. Statistical significance 3 
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RESULTS 1 
Cohort characteristics  2 
We identified 63,605 eligible subjects. Table 1 shows the baseline characteristics of 3 
the cohort. Out of 54,594 subjects with available ethnicity data, 54,219 (99.3%) were 4 
Asian. The mean age of receiving clarithromycin-based triple therapy was 55.6 (±14.6) 5 
years, and 46.6% were male. There were 15,990 (25.1%) statin users in the cohort 6 
(simvastatin:12,578 [78.7%]; atorvastatin:532 [3.3%]; rosuvastatin:275 [1.7%]; use of 7 
two or more statins at different times: 2605 [16.3%]). Before PS matching, most of 8 
the baseline characteristics were imbalance between statin and non-statin users. 9 
However, there was no statistically significant difference in the median number of 10 
upper endoscopies (statin users: 2, IQR:1.5–3 vs non-statin users: 2, IQR: 1–11 
3;p=0.892). After PS matching, a balance of covariates were achieved between the 12 
two groups except for chronic renal failure (ASD > 0.2), which was adjusted for in the 13 
subsequent competing risk regression model.  14 
 15 
Risk of gastric cancer development  16 
During a median follow up of 7.6 years (IQR:5.1–10.3) with 484,680 person-years, 17 
169 (0.27%) patients were diagnosed with gastric cancer at an incidence rate of 3.5 18 
per 10,000 person-years. Gastric cancer patients were diagnosed at a median of 71.1 19 
years (IQR:61.6–81.8), and they received eradication therapy at a median of 66.7 20 
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years (IQR:56.6–76.5). The location of these cancers were as follows: 34 (20.1%) in 1 
cardia, 98 (58.0%) in non-cardia region, and site was unspecified in 37 (21.9%) cases.  2 
 3 
Relationship between statins and gastric cancer  4 
The median duration of statin use was 3.6 years (IQR:1.6–5.9), with a median cDDD 5 
of 432 (IQR:181.6–323.2). Thirty-one (0.19%) of 15,990 statin users developed 6 
gastric cancer (crude incidence rate: 2.4 per 10,000 person-years). In contrast, 138 7 
(0.29%) non-statin users developed gastric cancer (crude incidence rate: 3.8 per 8 
10,000 person-years). After PS matching, statins were associated with a lower gastric 9 
cancer risk (adjusted SHR:0.34, 95% CI:0.19–0.61) (Table 2). The PS adjusted 10 
absolute risk difference was 2.6 fewer gastric cancers (95% CI:1.56–3.12) per 10,000 11 
person-years when comparing statin with non-statin use. Figure 2 shows the Kaplan 12 
Meier plot of gastric cancer incidence among statin and non-statin users (log-rank 13 
p<0.001). Stratified analysis shows statins remained protective for non-cardia cancer 14 
(SHR:0.48, 95% CI:0.24–0.98), but borderline significance was noted for cardia 15 
cancer (SHR:0.31, 95% CI:0.09–1.03). 16 
 17 
 18 
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Sensitivity analyses by changing days of exposure to define statin use to ≥ 30 and ≥ 1 
90 days show similar results ( ≥ 30-day use: SHR 0.34, 95% CI:0.20–0.59; p<0.001; ≥ 2 
90-day use: SHR 0.32, 95% CI:0.18–0.56; p<0.001;). By not including other 3 
comorbidities except for peptic ulcer disease and diabetes mellitus, the SHR was 0.45 4 
(95% CI:0.27–0.77; p=0.003). A total of 3,621 patients had prior statin use and were 5 
excluded for sensitivity analysis. The adjusted SHR was 0.26 (95% CI:0.12–0.55; 6 
p<0.001). Sensitivity analysis by competing risk regression model using PS 7 
regression adjustment with trimming and multivariable analysis yield similar results 8 
(Table 2). PS matching with Cox model also showed that adjusted HR of gastric 9 
cancer with statins was 0.29 (95% CI:0.16–0.52). When analyzing medications as 10 
time-varying covariates in the multivariable Cox model, the adjusted HR was 0.54 11 
(95% CI:0.35–0.87).  12 
 13 
Duration- and dose-response association between statins and gastric cancer     14 
Table 3 shows that a lower gastric cancer risk was observed among patients who used 15 
statins longer (SHR 0.46 [95% CI:0.25–0.86] for < 5 years of use and SHR 0.43 [95% 16 
CI:0.29–0.66] for ≥5 years of use; p-trend<0.001). In addition, the SHR of gastric 17 
cancer with every 100 increase in cDDD of statins was 0.90 (95% CI:0.81–0.99).  18 
 19 
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DISCUSSION 1 
Individuals can develop gastric cancer despite successful H. pylori eradication. In this 2 
cohort study of more than 63,000 patients with prior H. pylori treatment, we 3 
demonstrate that statins were associated with a 66% decrease in gastric cancer risk in 4 
a duration- and dose-dependent manner.  5 
 6 
To date, association between statins and gastric cancer remains elusive. Although a 7 
previous meta-analysis of 11 studies21 conclude that statins were associated with a 8 
lower risk of gastric cancer, one of the major limitations of the included studies was 9 
the failure to acknowledge the H. pylori status.21 The study by Chiu et al10 was the 10 
only one that adjusted for H. pylori eradication, but 85% of the patients had unknown 11 
H. pylori status in that study. Failure to account for this causative factor likely poses a 12 
significant impact on determining the causal relationship and magnitude of beneficial 13 
effect of statins on gastric cancer. In addition, gastric cancer was the primary outcome 14 
of interest in two studies only.10, 11 Also, inadequate adjustment for major risk factors 15 
(history of peptic ulcer diseases38, diabetes mellitus39 and medication usage 16 
[aspirin/NSAIDs,40, 41 metformin42 and PPIs43]) may either under- or over-estimate the 17 
effects of statins.44 Of note, post-hoc analyses of randomised controlled trials of 18 
cardiovascular studies included a relatively short follow-up duration, with potential 19 
ascertainment bias and bias from competing risks.44  20 
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 1 
Although being an observational study, our study had a large sample size (>63,000) 2 
with long follow-up duration (median 7.6 years), eliminated the confounding effect of 3 
H. pylori infection, and used PS matching to minimise bias. Importantly, few studies 4 
systematically evaluated the duration- and dose-response of statins use.44 The 5 
chemopreventive effects of statins shown in this study (SHR 0.34) was greater than 6 
that reported by previous studies (odds ratios ranging from 0.68 to 0.84)10, 12, 13, 7 
except for the study by Lee et al11 which recruited patients with diabetes mellitus only 8 
(odds ratio: 0.21). The greater risk reduction observed in this study could be due to 9 
the inclusion of subjects with prior H. pylori infection, therefore having a higher 10 
gastric cancer risk. We also performed stratified analysis according to cancer site, 11 
which had not been performed in any of the previous studies. We found that statins 12 
was protective against non-cardia cancer, while the beneficial effect was of borderline 13 
significance for cardia cancer (SHR of 0.31 with p=0.055). This result should be 14 
interpreted with caution due to underpower (number of cardia cancer cases=34). 15 
Lastly, our study used the territory-wide healthcare database with complete capture of 16 
diagnosis, drug prescription and dispensing records, which could address potential 17 
selection, information and recall biases of previous observational studies.45 18 
Surveillance or ascertainment bias was unlikely as there existed no difference in the 19 
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number of upper endoscopies between the statin and non-statin users. The robustness 1 
of the result was further supported by various sensitivity analyses, in particular by 2 
using time-varying covariates in treating all medications to address potential immortal 3 
time bias. Furthermore, as statin users generally had more comorbidities like 4 
cardiovascular diseases and diabetes mellitus (Table 1), this negates the concern of 5 
healthy user bias.46 As such, any beneficial effect of statin would only be 6 
underestimated (i.e. biased towards null).  7 
 8 
There are several limitations of this study. First, residual and unmeasured 9 
confounding may still exist for an observational study despite PS matching. Second, 10 
information on some risk factors were unavailable in our database, for instance, diet, 11 
body mass index, and family history. Third, the accuracy of diagnosis code could only 12 
be confirmed by validation of a small subset of gastric cancer patients who had 13 
follow-up in our institution. There is also likely an underestimation of prevalence of 14 
smoking and alcohol use with ICD-9 codes of COPD and alcohol-related diseases 15 
only, although the inclusion of a large set of comorbidities helps to act as surrogate 16 
markers for these two imperfectly measured confounders. Fourth, identification of 17 
patients with failure of clarithromycin-based triple therapy was indirect rather than 18 
based on the actual post-treatment H. pylori status since this information was 19 
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unavailable in the database. Nevertheless, the re-treatment rate of 13% in our study 1 
was consistent with that reported in our locality during the study period.28 H. pylori 2 
recurrence could not be ascertained in this database. However, a past local study 3 
showed an annual recurrence rate of 3.3% only.47 Fifth, compliance to medications 4 
could not be confirmed, although non-compliance will usually underestimate the 5 
beneficial effect of statins. Although data on over-the-counter (OTC) medication 6 
usage is unavailable, this is unlikely is a major concern as medications are dispensed 7 
at a very low cost from hospital pharmacy in Hong Kong. Unlike western countries, 8 
OTC purchase of aspirin is uncommon in Hong Kong. The leading anti-pyretic agent 9 
is paracetamol whereas NSAIDs are more often used in pain relief. Sixth, as data on 10 
baseline gastric histology was not available, we could not determine on what stages 11 
along the Correa cascade that statins exert the strongest effect. Lastly, generalizability 12 
of the study result to other statins is a concern, as the majority of patients (79%) were 13 
prescribed simvastatin. In addition, this study only focuses on the specific group of H. 14 
pylori-eradicated patients. Further research on the chemopreventive effects of statins 15 




on December 13, 2019. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on December 2, 2019; DOI: 10.1158/1055-9965.EPI-19-1044 
 23
CONCLUSIONS 1 
Long-term statin use associated a lower gastric cancer risk in a dose- and duration-2 
response manner among H. pylori-eradicated patients. Our findings may help in 3 
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Table 1. Baseline characteristics of study cohort before and after propensity score 1 
matching 2 
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Age of receiving triple therapy was expressed as mean (years) +/- 1 standard deviation 
Duration of follow-up was expressed as median (years) with interquartile range 
Categorical variables were expressed as number (%) 
Drug use was defined as use for more than 180 days, and expressed as number (%) 
Abbreviations: PS, propensity score; ASD, absolute standardized difference; GU, gastric ulcer; DU, duodenal 
ulcer; DM, diabetes mellitus; IHD, ischemic heart disease; AF, atrial fibrillation; CHF, congestive heart failure; 
CRF, chronic renal failure; NSAIDs, non-steroidal anti-inflammatory drugs; COX-2, cyclooxygenase-2; PPIs, 
proton pump inhibitors 
* PS matching was performed after trimming of the extreme PS strata (5th and 95th percentiles). Non-statin users 
were matched to statin users on PS within a caliper width of 0.1. All variables were included in the model for PS 
estimation  
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Table 2. Association between statin use and gastric cancer risk (whole cohort and 1 























































































0.017 0.48 0.24– 
0.98 
0.044 0.33 0.17– 
0.65 
































Ref - - Ref - - Ref - - Ref - - 
Statin 
use 
0.83 0.39–  
1.90 
0.660 n.a.# n.a.# n.a.# 0.31 0.09– 
1.03 
0.055 n.a.# n.a.# n.a.# 
Statin use was defined as use for more than 180 days 
Abbreviations: PS, propensity score; SHR, subdistribution hazard ratio; 95% CI, 95% confidence interval; PS, propensity 
score; GC, gastric cancer 
* PS analysis was performed after trimming of the extreme PS strata (5th and 95th percentiles) 
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Table 3. Association between duration and dose of statin use and gastric cancer risk 1 
(propensity score adjustment) 2 
 3 
Statin use SHR* 95% CI p-value p-trend 
Duration 
Non-statin use Ref - -  
<0.001 < 5 years 0.46 0.25 – 0.86 0.015 
≥ 5 years 0.43 0.29 – 0.66 <0.001 
Dose 
Non-statin use Ref - -  
Statin use (for every 100 
increase in cDDD) 
0.90 0.81 – 0.99 0.037  
Abbreviations: SHR, subdistribution hazard ratio; 95% CI, 95% confidence interval 
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FIGURE LEGENDS 1 
 2 
Figure 1: Patient selection flow diagram 3 
Abbreviations: GC, gastric cancer 4 
 5 
 6 
Figure 2: Kaplan Meier plot of gastric cancer incidence among propensity score 7 
matched statin and non-statin users  8 
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